Dechra Pharmaceuticals (LSE:DPH) Change In Receivables : £-21.5 Mil (TTM As of Jun. 2023)

View and export this data going back to 2000. Start your Free Trial

What is Dechra Pharmaceuticals Change In Receivables?

Dechra Pharmaceuticals's change in receivables for the quarter that ended in Jun. 2023 was £-42.1 Mil. It means Dechra Pharmaceuticals's Accounts Receivable increased by £42.1 Mil from Dec. 2022 to Jun. 2023 .

Dechra Pharmaceuticals's change in receivables for the fiscal year that ended in Jun. 2023 was £-21.5 Mil. It means Dechra Pharmaceuticals's Accounts Receivable increased by £21.5 Mil from Jun. 2022 to Jun. 2023 .

Dechra Pharmaceuticals's Accounts Receivable for the quarter that ended in Jun. 2023 was £144.2 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Dechra Pharmaceuticals's Days Sales Outstanding for the six months ended in Jun. 2023 was 68.51.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Dechra Pharmaceuticals's liquidation value for the six months ended in Jun. 2023 was £-523.0 Mil.

Dechra Pharmaceuticals Change In Receivables Historical Data

The historical data trend for Dechra Pharmaceuticals's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dechra Pharmaceuticals Change In Receivables Chart

Dechra Pharmaceuticals Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Change In Receivables

Get a 7-Day Free Trial

-11.70

6.90

-19.70

-23.40

-21.50

Dechra Pharmaceuticals Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Change In Receivables	Get a 7-Day Free Trial															-23.00	19.10	-42.50	20.60	-42.10

Dechra Pharmaceuticals Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was £-21.5 Mil.

Dechra Pharmaceuticals (LSE:DPH) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Dechra Pharmaceuticals's Days Sales Outstanding for the quarter that ended in Jun. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	144.2	/	384.1	*	91
=	68.51

2. In Ben Graham's calculation of liquidation value, Dechra Pharmaceuticals's accounts receivable are only considered to be worth 75% of book value:

Dechra Pharmaceuticals's liquidation value for the quarter that ended in Jun. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	74.4	-	814.2	+	0.75 * 144.2	+	0.5 * 217.3
=	-523.0

Dechra Pharmaceuticals Change In Receivables Related Terms

Thank you for viewing the detailed overview of Dechra Pharmaceuticals's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Dechra Pharmaceuticals (LSE:DPH) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Dechra Pharmaceuticals PLC (LSE:DPH) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

DPHAY:USA DPHl:UK 1PK:Germany

Address

24 Cheshire Avenue, Cheshire Business Park, Lostock Gralam, Northwich, GBR, CW9 7UA

Website

https://www.dechra.com

Dechra Pharmaceuticals PLC is a major drug manufacturing company with a focus on veterinary pharmaceutical products. The company develops, manufactures, and markets its products exclusively for veterinarians globally. Dechra is structured along three segments, including being European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals Research and Development. The vast majority of Dechra's revenue is generated in Europe, followed by the U.S. Dechra derives most of its revenue through its Companion Animal Product category, followed by food-producing animal products.

Dechra Pharmaceuticals (LSE:DPH) Headlines

No Headlines